Latanoprost API Secures MFDS Approval in Korea — Strategic Expansion into the Global Glaucoma Market

Everlight Chemical’s Latanoprost API has officially received drug product approval from the Korean Ministry of Food and Drug Safety (MFDS), marking a significant milestone in our expansion into the Korean pharmaceutical market.

Latanoprost：A Globally Preferred First-Line Treatment for Glaucoma

Latanoprost is a prostaglandin analog widely recognized as a first-line therapy for glaucoma and ocular hypertension. It works by increasing the outflow of aqueous humor from the eyes, thereby effectively lowering intraocular pressure (IOP), helping to prevent optic nerve damage and vision loss. Thanks to its once-daily dosing and consistent efficacy, Latanoprost is widely accepted and recommended by ophthalmologists worldwide.

According to the Health Insurance Review & Assessment Service (HIRA)1 of Korea and multiple research studies2, the number of glaucoma patients in Korea has been steadily rising. In 2023, more than 1.2 million people in Korea received treatment for glaucoma. As the aging population continues to grow, the prevalence of glaucoma is expected to increase further, driving demand for safe and effective treatment options.

Everlight Chemical: Your Reliable Partner for High-Quality Latanoprost API

This MFDS approval demonstrates Everlight Chemical’s capability to meet stringent international pharmaceutical manufacturing and quality standards. It also reinforces our long-term commitment to Asia’s healthcare market. With this approval, our Latanoprost API can now be legally and reliably supplied to the Korean market, positioning us as a trusted API provider for local pharmaceutical companies.

We offer:

  • Complete DMF and regulatory documentation to support fast product registration
  • Flexible production scheduling and a stable supply chain
  • cGMP-compliant manufacturing with extensive multinational audit experience

Creating Value Together – Let’s Expand the Global Market

Everlight Chemical is committed to being a trustworthy API partner for pharmaceutical developers worldwide. Whether you’re a branded or generic pharmaceutical company seeking a stable, high-quality API supplier, we welcome the opportunity to collaborate and unlock new market opportunities together.

References：

  1. Health Insurance Review & Assessment Service (HIRA), Korea
    – Annual Statistics on Ophthalmic Diseases – 2023, According to HIRA data, over 1.2 million people in Korea received glaucoma-related treatment in 2023, marking an increase of more than 30% compared to 2015. Glaucoma is one of the most common chronic eye conditions among the elderly, and its prevalence continues to rise with Korea’s aging population.
    – Data available at:https://www.hira.or.kr (Search for「녹내장」= Glaucoma)
  2. Journal of Korean Ophthalmology & Clinical Reports (2022)
    Studies cited indicate that the prevalence of glaucoma among Korean adults aged 40 and above ranges between 4.5% and 5.6%, placing Korea among the countries in Asia with the highest prevalence rates.